Treating depression in patients with ischaemic heart disease. Which agents are best to use and to avoid?

Drug Safety

Volumn 20, Issue 5, 1999, Pages 459-465

  Roose, Steven P ^a   Spatz, Erica ^b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; FLUOXETINE; MORACIZINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CARDIOVASCULAR EFFECT; DEPRESSION; DISEASE SEVERITY; DRUG SAFETY; HEART DISEASE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032923255     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920050-00006     Document Type: Review

References (25)

1. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93: 1231-8
2. Black DW, Warrack G, Winokur G. The Iowa record-linkage study: III: excess mortality among patients with 'functional' disorders. Arch Gen Psychiatry 1985; 42: 82-8
3. Weeke A. Causes of death in manic-depressives. In: Schou M, Stromgren E, editors. Origin, prevention and treatment of affective disorders. London: Academic Press, 1979: 289-99
4. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990; 264: 1546-9
5. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 411
6. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 627-33
7. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 1785-9
8. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270: 1819-25
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
10. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005
11. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 1976; 33: 1029-37
12. Roose SP, Glassman AH. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease [abstract]. J Clin Psychiatry 1989; 50 Suppl.: 118
13. Glassman AH, Roose SP, Bigger JT, Jr. The safety of tricyclic antidepressants in cardiac patients: risk/benefit reconsidered. JAMA 1993; 269: 2673-5
14. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12
15. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33
16. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107-11
17. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16
18. Greenberg HM, Dwyer EM, Jr., Hochman JS, et al. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST 1. Br Heart J 1995; 74: 631-5
19. Roose SP, Dalaek GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148: 512-6
20. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155 (5): 660-5
21. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287-91
22. Hamilton MA. Rating for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
23. Shapiro PA, Glassman AH, Lesperance F, et al. Treatment of major depression after acute myocardial infarction with sertraline: a preliminary study. Proceedings of the American Psychiatric Association: New York: New Research, 1996: 249-50
24. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151; 1735-9
25. Zielinski, RJ, Roose SP, Devanand DP, et al. Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 1993; 150: 904-9